ROS1 REARRANGEMENT Detail (hg38) (ROS1)

Information

Genome

Assembly Position
hg19 chr6:117,609,463-117,747,018 View the variant detail on this assembly version.
 
hg38 chr6:117,288,300-117,425,855
 
Summary

MGeND

Clinical significance
Variant entry
GWAS entry
Disease area statistics Show details

ClinVar

Clinical Significance
Review star [No Data.]
Show details
Links
Type Database ID Link
Gene MIM 165020 OMIM
HGNC 10261 HGNC
Ensembl ENSG00000047936 Ensembl
NCBI NCBI
Gene Cards Gene Cards
OncoKB OncoKB
Type Database ID Link
Variant TogoVar
COSMIC
MONDO
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
Disease Drug EL ET ED CS VO TR Pubmed Links
lung non-small cell carcinoma Crizotinib B Predictive Supports Sensitivity/Response Somatic 3 25667280 Detail
lung adenocarcinoma Ceritinib C Predictive Supports Sensitivity/Response Somatic 1 26917690 Detail
colorectal adenocarcinoma Crizotinib E Predictive Supports Sensitivity/Response Somatic 2 24296758 Detail
bronchiolo-alveolar adenocarcinoma Crizotinib C Predictive Supports Sensitivity/Response Somatic 3 22215748 Detail
lung adenocarcinoma Crizotinib C Predictive Supports Sensitivity/Response Somatic 3 25922291 Detail
cancer Entrectinib B Predictive Supports Sensitivity/Response Somatic 3 28183697 Detail
lung non-small cell carcinoma Crizotinib B Predictive Supports Sensitivity/Response Somatic 4 25264305 Detail
DisGeNET
[No Data.]
Annotation

Annotations

DescrptionSourceLinks
In a retrospective study, 30 patients were evaluated after crizotinib treatment for stage IV NSCLC c... CIViC Evidence Detail
Case report of a 77-year old male patient with lung adenocarcinoma (T2aN1M0, stage IIA) without EGFR... CIViC Evidence Detail
A tissue microarray of 268 patients with histologically confirmed colorectal adenocarcinoma was perf... CIViC Evidence Detail
Study describes a 31-year old male, never-smoker patient with advanced NSCLC with a ROS1 rearrangeme... CIViC Evidence Detail
In an evaluation of a patient and never smoker with crizotinib-sensitive lung adenocarcinoma, an SDC... CIViC Evidence Detail
Two phase I studies in patients with advanced or metastatic solid tumors, including patients with ac... CIViC Evidence Detail
An expansion cohort of a phase-1 Crizotinib study found a 72% objective response rate among 50 patie... CIViC Evidence Detail
Gene
ROS1
Genome
hg38
Position
chr6:117,288,300-117,425,855
Variant Type
fusion
Variant (CIViC) (CIViC Variant)
REARRANGEMENT
Transcript 1 (CIViC Variant)
ENST00000368508.3
Variant URL (CIViC Variant)
https://civic.genome.wustl.edu/links/variants/269
Summary (CIViC Variant)
ROS1 is a receptor tyrosine kinase that frequently forms gene fusions in several cancer types. Approximately 2% of NSCLC patients harbor a ROS1 gene fusion. Several fusion partners have been described with a constant ROS1-breakpoint, maintaining the kinase domain (Solomon B, 2015). Following case-studies and retrospective analyses, an expansion cohort of a phase-1 study showed clinical benefit of crizotinib in ROS1 rearranged NSCLC. The benefit was independent of the type of ROS1-rearrangement (Shaw et. al.,2014).
Genome browser